Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04847531 · ClinicalTrials.gov registry record
REVEAL-CKD: Prevalence and Consequences of Undiagnosed Chronic Kidney Disease
A clinical trial, sponsored by AstraZeneca.
- Completed
- Registry status
- 1,006,361
- Enrollment target
NCT04847531 is a clinical trial that has completed, run by AstraZeneca. The registered enrollment target is 1,006,361 participants.
The verdict
NCT04847531 has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 1,006,361 participants
- Enrollment target
Study Summary
This is a retrospective, multinational, non-interventional, observational study. A series of cohort studies will be conducted to assess the prevalence of undiagnosed stage 3 CKD in each region. The study will also assess the current state of CKD management in patients with undiagnosed CKD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,006,361 participants |
| Start Date | 2020-12-15 |
| Est. Completion | 2023-11-13 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04847531
The ClinicalTrials.gov registry entry for NCT04847531 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,006,361 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT04847531 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04847531 about?
NCT04847531 is a clinical study titled "REVEAL-CKD: Prevalence and Consequences of Undiagnosed Chronic Kidney Disease". This is a retrospective, multinational, non-interventional, observational study. A series of cohort studies will be conducted to assess the prevalence of undiagnosed stage 3 CKD in each region. The study will also assess the current state of CKD management in patients with undiagnosed CKD
What is the current status of trial NCT04847531?
This trial is currently completed. The enrollment target is 1,006,361 participants. The study started on 2020-12-15. Estimated completion is 2023-11-13.
Who is sponsoring clinical trial NCT04847531?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.